Gene Predictis SA, a Swiss precision medicine company offering tools to optimize drug treatments, is a winner of the European Venture Contest 2015. The company was selected from over 1’000 companies in high technology sector, by an international investors jury composed of over 100 investors and business angels, based on its technology and business opportunity, as one of the most promising companies in Europe in the Life Sciences field.

The contest was organised by Europe Unlimited and took place in Düsseldorf, Germany, on December 7 and 8, 2015.

Gene Predictis®, a Swiss precision medicine company, has completed an international clinical validation study for Pill Protect®, an innovative medical test that uses genetic data to identify women at risk of developing blood clots (thrombosis) when using contraceptive pills. The test was shown to identify over 8 times more women at risk than today standard of care, making Pill Protect® the best available test. Already proposed in Switzerland and reimbursed by the insurances, the test helps to identify women at risk of thrombotic disease and facilitate the decision process for medical doctors helping them to propose the most optimal and safest contraceptive pill/method for every woman.

Press release_Pill Protect_september 2015_ang

Gene Preditis has been awarded the CTI Start-Up Label on September 10th, 2013  by the Commission for Technology and Innovation CTI, Swiss Confederation. The Start-up Label is a seal of quality, a certificate of achievement, and a sign of credibility and readiness for sustainable growth.

In August 2012, Gene Predictis SA moved its headquarters and laboratories to the Science Park EPFL in Lausanne. Today, we have a pleasure to inaugurate our new space and present you our products.